Robotics company announces closing of investment round, raising $14 million

Robotics company, Andrew Alliance, has announced a $14 million investment from several of the leading life sciences enterprises, including Tecan Group, Waters Corporation, Inpeco, Rancilio Cube, Sam Eletr Trust and Omega Funds.

“We are delighted to expand our team of investors and partners with the industry’s most recognised companies,” explained Piero Zucchelli, CEO and a co-founder of Andrew Alliance. “It’s particularly meaningful that both Tecan and Waters appreciate how we’re making robotics accessible to more scientists.”

“Andrew Alliance’s robot changes the game for repeatability — and further improves our customers’ operational efficiency,” said Paul Tardif, senior director of corporate development at Waters. “The Andrew robots are extraordinarily affordable and solve a persistent problem. Our customers are eager for a ready-to-use solution like this.”

The company’s flagship offering is a family of flexible, software-driven robot models, each with a footprint about the size of a standard piece of paper. These robots work right out of the box and deliver consistency in how liquids are measured and tested, using standard pipettes and consumables.

“Andrew Alliance’s affordable benchtop robotics using conventional pipettes is a new and complementary approach to Tecan’s workstations, which help customers to automate a wide variety of laboratory workflows in research and clinical diagnostics,” added David Martyr, CEO of Tecan.

This round of investment brings together a strategic mix of global life science companies with private equity investors and existing investors. The funds will be used for continuous product innovation and strategic industry partnerships. The company will also extend its close collaboration with customers worldwide to refine future offerings.

“Demand for better reproducibility continues to increase,” remarked Otello Stampacchia, managing director and founder of Omega Funds, an early investor. “We are delighted to work with Andrew Alliance to address this major issue.”

“The ongoing innovation in life science creates a vast opportunity for new automated tools and approaches like Andrew Alliance’s robots,” said Sam Eletr, a member of the founding team and an early investor.